(FORTUNE Small Business) – A food and drug administration advisory panel has dealt a setback to the artificial heart made by Abiomed, the Danvers, Mass., firm that FSB profiled in May. The panel decided that the device's risks, including stroke, outweighed its benefits, and recommended it not be approved by the FDA for use as a last resort in dying heart patients. (Fourteen patients have undergone clinical trials; they lived an average of five months.) The FDA usually, but not always, follows the panel's advice. Abiomed says it will provide more information to the FDA and may test the device on more patients. --PATRICIA B. GRAY